← Product Code [GSO](/submissions/MI/subpart-d%E2%80%94serological-reagents/GSO) · K972396

# VISTA ANTIGEN BRUCELLA MELITENSIS (K972396)

_Lee Laboratories, Inc. · GSO · Aug 25, 1997 · Microbiology · SESE_

**Canonical URL:** https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/GSO/K972396

## Device Facts

- **Applicant:** Lee Laboratories, Inc.
- **Product Code:** [GSO](/submissions/MI/subpart-d%E2%80%94serological-reagents/GSO.md)
- **Decision Date:** Aug 25, 1997
- **Decision:** SESE
- **Submission Type:** Traditional
- **Regulation:** 21 CFR 866.3085
- **Device Class:** Class 2
- **Review Panel:** Microbiology

## Indications for Use

Screening for and/or confirmation of certain febrile diseases by the detection of antibodies in serum

## Device Story

VISTA™ Antigen Brucella melitensis is an in-vitro diagnostic reagent used for the detection of antibodies in human serum. It facilitates the screening and confirmation of febrile diseases. The device is intended for use in clinical laboratory settings by trained personnel. The output provides qualitative or semi-quantitative results regarding the presence of antibodies, which assists clinicians in diagnosing febrile illnesses. The device aids in clinical decision-making by identifying specific pathogen exposure, thereby guiding appropriate patient management and treatment strategies.

## Clinical Evidence

No clinical data provided in the document; the submission relies on the determination of substantial equivalence to legally marketed predicate devices.

## Technological Characteristics

In-vitro diagnostic antigen reagent for antibody detection. Formulated for laboratory use. No specific materials, energy sources, or software algorithms described.

## Regulatory Identification

Brucella spp. serological reagents are devices that consist of antigens and antisera used for serological identification of Brucella spp. from cultured isolates derived from clinical specimens or to identify antibodies to Brucella spp. in serum. Additionally, some of these reagents consist of antisera conjugated with a fluorescent dye (immunofluorescent reagents) used to identify Brucella spp. directly from clinical specimens or cultured isolates derived from clinical specimens. The identification aids in the diagnosis of brucellosis (e.g., undulant fever, Malta fever) caused by bacteria belonging to the genus Brucella and provides epidemiological information on diseases caused by these microorganisms.

## Special Controls

*Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 866.9.

## Submission Summary (Full Text)

> This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com.
>
> Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/).

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features a stylized abstract design resembling an eagle or a person with outstretched arms. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" is arranged in a circular fashion around the design.

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

Robin C. Hart, Ph.D. Ouality Assurance/Regulatory Affairs Manager · Lee Laboratories 1475 Athens Highway Grayson, GA 30221

AUG 25 1997

Re: K972396 Trade Name: VISTA™ Antigen Brucella melitensis Regulatory Class: II Product Code: GSO Dated: June 24, 1997 Received: June 26, 1997

Dear Dr. Hart:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

{1}------------------------------------------------

Page 2

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in-vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".

Sincerely yours,

Steven Sutman

Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

510(k) Number (if known): _

VISTATM Antigen Brucella melitensis Device Name: _________________________________________________________________________________________________________________________________________________________________

Indications For Use:

Screening for and/or confirmation of certain febrile diseases by the detection of antibodies in serum

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

. / .

Concurrence of CDRH, Office of Device Evaluation (ODE)

Arlen Pink

Over-The-Counter Use _________________________________________________________________________________________________________________________________________________________

(Division Sign-Off) Division of Clinical Laboratory Devices

510(k) Number Off

Prescription Use i (Per 21 CFR 801.109)

(10)

---

**Source:** [https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/GSO/K972396](https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/GSO/K972396)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com